In vitro NASH Fee-For-Service by CN Bio

Manufacturer CN Bio  |  Available Worldwide
CN Bio supports R&D efforts to discover much needed non-alcoholic steatohepatitis (NASH) therapeutics via a fast-track NASH Fee-For-service. This screening service provides access to the Company’s expertise and one of the most advanced human in vitro models currently available. It delivers translatable human data for more insightful pre-clinical candidate prioritization, clinical trial design and optimization.


In vitro NASH Fee-For-Service by CN Bio product image
In vitro NASH Fee-For-Service
Request Pricing

Receive your quote directly from the manufacturer.



0 Scientists have reviewed this product


Write the First Review

No Reviews

After years of costly research and development, many drug discovery programs fail because 2D cell culture and animal models do not adequately predict human responses. To mitigate the risk of late-stage failures in the clinic, researchers are increasingly adopting OOC technology to predict drug efficacy, toxicity, and pharmacokinetic profiles early in programs. Insights generated using OOC are being used to complement data derived using traditional methods, confirm discoveries, overcome inter-species differences, and bridge knowledge gaps. However, in certain scenarios, such as the development of new human-specific modalities, OOC offers a novel opportunity to validate a target hypothesis, test safety and efficacy where animal models may be altogether unsuitable due to differences in gene sequence or immunological response.  

Product Overview

In vitro NASH Fee-For-Service by CN Bio product image

In vitro NASH Fee-For-Service

Manufacturer CN Bio  |  Available Worldwide

Be the first to review this product